A Pilot Study of All-Computational Drug Design Protocol–From Structure Prediction to Interaction Analysis
暂无分享,去创建一个
Lei Lou | Yifei Wu | Zhong-Ru Xie | Zhong-Ru Xie | Yifei Wu | Lei Lou
[1] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[2] W. Zhou,et al. International Journal of Molecular Sciences Systems Pharmacology in Small Molecular Drug Discovery , 2022 .
[3] Devadasan Velmurugan,et al. Identification of Natural Compound Inhibitors for Multidrug Efflux Pumps of Escherichia coli and Pseudomonas aeruginosa Using In Silico High-Throughput Virtual Screening and In Vitro Validation , 2014, PloS one.
[4] Jeremy R. Greenwood,et al. Epik: a software program for pKa prediction and protonation state generation for drug-like molecules , 2007, J. Comput. Aided Mol. Des..
[5] Thomas A. Halgren,et al. Identifying and Characterizing Binding Sites and Assessing Druggability , 2009, J. Chem. Inf. Model..
[6] Alexander D. MacKerell,et al. Automation of the CHARMM General Force Field (CGenFF) II: Assignment of Bonded Parameters and Partial Atomic Charges , 2012, J. Chem. Inf. Model..
[7] J. Kinney,et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.
[8] Ling Lu,et al. α-Actinin2 cytoskeletal protein is required for the functional membrane localization of a Ca2+-activated K+ channel (SK2 channel) , 2009, Proceedings of the National Academy of Sciences.
[9] D. Ramotar,et al. A novel approach using C. elegans DNA damage-induced apoptosis to characterize the dynamics of uptake transporters for therapeutic drug discoveries , 2016, Scientific Reports.
[10] Ming-Jing Hwang,et al. Ligand-binding site prediction using ligand-interacting and binding site-enriched protein triangles , 2012, Bioinform..
[11] J. Thornton,et al. PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .
[12] Alexander D. MacKerell,et al. Automation of the CHARMM General Force Field (CGenFF) I: Bond Perception and Atom Typing , 2012, J. Chem. Inf. Model..
[13] L. Jardim,et al. Riluzole in patients with hereditary cerebellar ataxia , 2016, The Lancet Neurology.
[14] Alexander D. MacKerell,et al. Extension of the CHARMM general force field to sulfonyl‐containing compounds and its utility in biomolecular simulations , 2012, J. Comput. Chem..
[15] Jacob D. Durrant,et al. Molecular dynamics simulations and drug discovery , 2011, BMC Biology.
[16] Ralf Blossey,et al. Molecular docking as a popular tool in drug design, an in silico travel , 2016, Advances and applications in bioinformatics and chemistry : AABC.
[17] C. Glabe,et al. Familial Alzheimer's Disease Mutations within the Amyloid Precursor Protein Alter the Aggregation and Conformation of the Amyloid-β Peptide* , 2017, The Journal of Biological Chemistry.
[18] Robert Abel,et al. Accelerating drug discovery through tight integration of expert molecular design and predictive scoring. , 2017, Current opinion in structural biology.
[19] L. McNamee,et al. Contribution of NIH funding to new drug approvals 2010–2016 , 2018, Proceedings of the National Academy of Sciences.
[20] F. Orzi,et al. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial , 2015, The Lancet Neurology.
[21] J. Skolnick,et al. TM-align: a protein structure alignment algorithm based on the TM-score , 2005, Nucleic acids research.
[22] R. Friesner,et al. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. , 2006, Bioorganic & medicinal chemistry.
[23] Ming-Jing Hwang,et al. Methods for predicting protein-ligand binding sites. , 2015, Methods in molecular biology.
[24] R. Friesner,et al. The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling , 2011, Proteins.
[25] Woody Sherman,et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.
[26] Torsten Schwede,et al. SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..
[27] G. P. Sinha,et al. Mutations in CIB2, a calcium and integrin binding protein, cause Usher syndrome type 1J and nonsyndromic deafness DFNB48 , 2012, Nature Genetics.
[28] Jerry R. Hobbs,et al. An Intracellular Allosteric Modulator Binding Pocket in SK2 Ion Channels Is Shared by Multiple Chemotypes. , 2018, Structure.
[29] Antonio Lavecchia,et al. Machine-learning approaches in drug discovery: methods and applications. , 2015, Drug discovery today.
[30] R. Friesner,et al. Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.
[31] Alán Aspuru-Guzik,et al. Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules , 2016, ACS central science.
[32] Alexander D. MacKerell,et al. CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..
[33] Pratyush Tiwary,et al. Prediction of Protein-Ligand Binding Poses via a Combination of Induced Fit Docking and Metadynamics Simulations. , 2016, Journal of chemical theory and computation.
[34] A. Jemal,et al. Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[35] Gerhard Wolber,et al. The impact of molecular dynamics on drug design: applications for the characterization of ligand-macromolecule complexes. , 2015, Drug discovery today.
[36] Torsten Schwede,et al. The SWISS-MODEL Repository: new features and functionalities , 2005, Nucleic Acids Res..
[37] Tom Halgren,et al. New Method for Fast and Accurate Binding‐site Identification and Analysis , 2007, Chemical biology & drug design.
[38] D. Strøbæk,et al. CyPPA, a Positive SK3/SK2 Modulator, Reduces Activity of Dopaminergic Neurons, Inhibits Dopamine Release, and Counteracts Hyperdopaminergic Behaviors Induced by Methylphenidate1 , 2012, Front. Pharmacol..
[39] Evan Bolton,et al. PubChem 2019 update: improved access to chemical data , 2018, Nucleic Acids Res..
[40] J. Pascal,et al. Unstructured to structured transition of an intrinsically disordered protein peptide in coupling Ca2+-sensing and SK channel activation , 2013, Proceedings of the National Academy of Sciences.
[41] Justin A. Lemkul,et al. Parametrization of halogen bonds in the CHARMM general force field: Improved treatment of ligand-protein interactions. , 2016, Bioorganic & medicinal chemistry.
[42] J. Adelman,et al. SK channels in excitability, pacemaking and synaptic integration , 2005, Current Opinion in Neurobiology.
[43] Woody Sherman,et al. Use of an Induced Fit Receptor Structure in Virtual Screening , 2006, Chemical biology & drug design.
[44] S. S. Imam,et al. Computer Aided Drug Design: A Novel Loom To Drug Discovery , 2017 .
[45] Jennifer L. Knight,et al. OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. , 2016, Journal of chemical theory and computation.
[46] George Hripcsak,et al. Computational Drug Target Screening through Protein Interaction Profiles , 2016, Scientific Reports.
[47] Christian Kramer,et al. MM/GBSA Binding Energy Prediction on the PDBbind Data Set: Successes, Failures, and Directions for Further Improvement , 2013, J. Chem. Inf. Model..